OPPM
FOLD

Opus Point Partners Management’s Amicus Therapeutics FOLD Stock Holding History

Opus Point Partners Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-36,731
Closed -$458K – 59
2019
Q2 		$458K Hold
36,731
– – 0.68% 40
2019
Q1 		$500K Buy
+36,731
New +$449K 0.68% 35

Other funds holding FOLD

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Opus Point Partners Management's FOLD Position: Q3 2019 in Review

Opus Point Partners Management sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 36,731 shares — an estimated $458K sold.

Opus Point Partners Management first reported a position in FOLD in Q1 2019 and held it in 2 quarters. The position peaked at $500K in Q1 2019. 205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Opus Point Partners Management reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 36,731 Amicus Therapeutics shares in Q3 2019, an estimated $458K.
  • Opus Point Partners Management first reported a position in Amicus Therapeutics in Q1 2019 and held it in 2 quarters.
  • Opus Point Partners Management's Amicus Therapeutics position peaked at $500K in Q1 2019.
  • 205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.